This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Posted by Hugh on January 10, 2019, at 10:03:10

In reply to SAGE-217 does well in phase 3 clinical trial, posted by Hugh on January 10, 2019, at 9:35:57

This clinical trial was for postpartum depression. The positive results mean that it's likely that SAGE-217 will be approved by the FDA later this year. If this happens, it can be prescribed off-label for major depressive disorder, bipolar I/II, and insomnia. (There are currently SAGE-217 clinical trials underway for these disorders.)

If it's approved by the FDA, SAGE-217 will be the first truly new class of antidepressant to appear since the SSRIs were introduced over thirty years ago.

Based on the results of earlier clinical trials, it appears that SAGE-217 might only have to be taken once a month, or even less frequently.

- SAGE-217 does well in phase 3 clinical trial
**Hugh**1/10/19 - Re: SAGE-217 does well in phase 3 clinical trial
**Hugh**1/10/19 - Re: SAGE-217 does well in phase 3 clinical trial
**Lamdage22**1/11/19 - Re: SAGE-217 does well in phase 3 clinical trial
**Hordak**1/12/19 - Re: SAGE-217 does well in phase 3 clinical trial
**Hugh**1/16/19

Psycho-Babble Medication | Framed

poster:Hugh
thread:1102732

URL: http://www.dr-bob.org/babble/20181024/msgs/1102733.html